Results 31 to 40 of about 28,931 (239)

Estrogen Receptor Beta and 2-arachidonoylglycerol Mediate the Suppressive Effects of Estradiol on Frequency of Postsynaptic Currents in Gonadotropin-Releasing Hormone Neurons of Metestrous Mice: An Acute Slice Electrophysiological Study. [PDF]

open access: yes, 2016
Gonadotropin-releasing hormone (GnRH) neurons are controlled by 17beta-estradiol (E2) contributing to the steroid feedback regulation of the reproductive axis.
Bálint, Flóra   +2 more
core   +1 more source

Effect of luteal phase support gonadotropin-releasing hormone agonist on the endometrial receptivity and outcomes of in vitro fertilization programs [PDF]

open access: yesГинекология, 2016
Patients with tubal infertility in implantation window period show impaired endometrial receptivity with low implantation potention that is characterized by decrease in mature pinopodes level on endometrium, decreased expression of leukemia inhibitory ...
E M Savelyeva   +3 more
doaj  

Final oocyte maturation with a dual trigger compared to human chorionic gonadotropin trigger in antagonist co-treated cycles: A randomized clinical trial

open access: yesMiddle East Fertility Society Journal, 2018
Objective: This clinical trial compared the effect of a dual trigger treatment (combination of gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) and hCG alone on oocyte quality and metaphase II oocytes’ number. Methods:
Ashraf Alleyassin   +8 more
doaj   +1 more source

Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Basios, George   +4 more
core   +1 more source

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention

open access: yesUpsala Journal of Medical Sciences, 2020
In this review the advantages of the gonadotropin-releasing hormone agonist (GnRHa) trigger are discussed beyond those immediately associated with ovarian hyperstimulation syndrome (OHSS) prevention.
Juan Carlos Castillo   +3 more
doaj   +1 more source

Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

open access: yesTherapeutic Advances in Urology, 2015
Objectives: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1,
Thiery Lebret   +7 more
doaj   +1 more source

Investigating the KNDy hypothesis in humans by co-administration of kisspeptin, neurokinin B and naltrexone in men [PDF]

open access: yes, 2016
Context: A subpopulation of hypothalamic neurons co-localise three neuropeptides namely kisspeptin, neurokinin B (NKB) and dynorphin collectively termed KNDy neurons. Animal studies suggest they interact to affect pulsatile GnRH release (KNDy hypothesis);
Abbara, A   +11 more
core   +1 more source

Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol

open access: yesFrontiers in Endocrinology, 2021
ObjectiveTo investigate the factors that influence luteal phase short-acting gonadotropin-releasing hormone agonist (GnRH-a) long protocol and GnRH-antagonist (GnRH-ant) protocol on pregnancy outcome and quantify the influence.
Jie Zhang   +8 more
doaj   +1 more source

Combined ovulation triggering with GnRH agonist and hCG in IVF patients [PDF]

open access: yes, 2016
The aim of the review is to analyse the combination of a gonadotrophin releasing hormone (GnRH) agonist with a human chorionic gonadotrophin (hCG) trigger, for final oocyte maturation in in vitro fertilisation (IVF) cycles.
Kasum, Miro   +5 more
core   +1 more source

Direct evidence on the efficacy of GnRH agonist in recurrent steroid cell tumor-not otherwise specified

open access: yesGynecologic Oncology Reports, 2019
Background: Steroid cell tumor (SCT) not otherwise specified (NOS) is rare and recurrence and metastasis rarely occurs; therefore, reports regarding its treatment are limited.
Tadaharu Nakasone   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy